Skip to main content

Fremanezumab News

FDA Approves Expanded Indication for Ajovy (fremanezumab-vfrm), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) – Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the...

Teva Announces FDA Approval of Ajovy (fremanezumab-vfrm) Injection Autoinjector

PARSIPPANY, N.J.--(BUSINESS WIRE) January 28, 2020 – Teva Pharmaceuticals USA, Inc. an affiliate ofTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the Food and Drug...

FDA Approves Ajovy (fremanezumab-vfrm) for Preventive Treatment of Migraine

September 14, 2018 – Today, the US Food and Drug Administration (FDA) approved Ajovy (fremanezumab-vfrm) for the preventive treatment of migraine in adults. Ajovy is the second FDA-approved...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Migraine Prevention, Migraine Prophylaxis, Chronic Migraine, Headache, Migraine

Related drug support groups

Ajovy

Fremanezumab patient information at Drugs.com